Skip to content

News

FDA Approves Bevacizumab Paired with Chemotherapy After Sur...

FDA Approves Bevacizumab Paired with Chemotherapy After Surgery for Advanced Ovarian Cancer

(June 29, 2018) Avastin, or bevacizumab, was recently approved by the FDA to be used first with chemotherapy, then by itself, after surgery. A phase III trial studied 1,873 women who had not had any prior treatments for stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma. Once the women had undergone … Continued

The 2018 American Association for Cancer Research Annual Me...

The 2018 American Association for Cancer Research Annual Meeting

(May 18, 2018) Just last month, three of OCRFA’s research advocates attended the 5 day AACR meeting in Chicago, Illinois to learn about new therapies and innovative technology, stay up to date on current projects, and attend lectures from ovarian cancer researchers such as Dr. Anil Sood of MD Anderson and Dr. Dineo Khabele of … Continued

Hormone Replacement Therapy After Oophorectomy Is Not Shown...

Hormone Replacement Therapy After Oophorectomy Is Not Shown to Increase Risk of Breast Cancer in BRCA1 Mutation Carriers

(May 4, 2018) JAMA Oncology recently published a study that looked at the risk of breast cancer in BRCA1 carriers who underwent a prophylactic bilateral salpingo-oophorectomy, a surgery that removes both ovaries before any sign of disease, followed by hormone replacement therapy (HRT). Eight hundred and seventy two women were followed for around 7.5 years … Continued

OCRFA Funded Study Focuses on the Dissemination of Ovarian ...

OCRFA Funded Study Focuses on the Dissemination of Ovarian Cancer

(April 27, 2018) An OCRFA supported study, recently published in Oncogene, delved into the mechanics of how ovarian cancer spreads throughout the body. Researchers at Johns Hopkins, including OCRFA grantee and lead author Ie-Ming Shih, MD, PhD, investigated spleen tyrosine kinase (SYK), which is heavily involved in ovarian cancer tumor progression, in an effort to … Continued

Study Shows Survival Advantage of Primary Cytoreductive Sur...

Study Shows Survival Advantage of Primary Cytoreductive Surgery

(April 26, 2018) The International Journal of Gynecological Cancer recently featured a retrospective study on the treatment patterns of women with advanced high-grade serous ovarian carcinoma (HGSC). Of the 852 women with HGSC included in the study, 53% of them underwent primary cytoreductive surgery (PCS), or surgery before chemotherapy to remove as much of the tumor … Continued

OCRFA Funded Study Explores Implant that Detects Ovarian Ca...

OCRFA Funded Study Explores Implant that Detects Ovarian Cancer Biomarker

(April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice. HE4, like CA-125, is approved by the U.S. Food and Drug Administration as a biomarker for HGSC. However, these biomarkers are more … Continued

Vaccine for Ovarian Cancer Shows Promising Results in Pilot...

Vaccine for Ovarian Cancer Shows Promising Results in Pilot Trial

(April 17, 2018) Science Translational Medicine recently published a University of Pennsylvania Perelman School of Medicine/University of Lausanne, Switzerland study on using a patient’s immune system to fight their cancer. In this pilot trial, 25 patients with advanced epithelial recurrent ovarian cancer were either given the vaccine alone, with the chemotherapy drug bevacizumab, or a … Continued

FDA Approves Rucaparib as Maintenance Treatment for Platinu...

FDA Approves Rucaparib as Maintenance Treatment for Platinum Sensitive Recurrent Ovarian Cancer

(April 10, 2018) Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least a partial response to platinum based chemotherapy have a new, FDA approved option for maintenance therapy. The evidence that led to the FDA approving rucaparib comes from the phase 3 ARIEL3 clinical trial, which enrolled 564 … Continued

Updates from 2018 Annual Meeting on Women’s Cancer

Updates from 2018 Annual Meeting on Women’s Cancer

(April 4, 2018) It’s an exciting time for ovarian cancer research! Ovarian cancer clinicians, researchers and advocates came together in New Orleans at the end of March for the Annual Meeting on Women’s Cancer, hosted by the Society of Gynecologic Oncology (SGO). Meeting attendees learned about the latest developments in ovarian cancer research, treatment, and … Continued

Genetic Counseling and Testing by Oncologists Feasible for ...

Genetic Counseling and Testing by Oncologists Feasible for Ovarian Cancer Patients

(April 3, 2018) A study in the Journal of Clinical Oncology explored the effects of oncologists, rather than genetic counselors, testing ovarian cancer patients for BRCA mutations. Due to the limited number of genetic counselors and the increase in demand for BRCA mutation testing, ovarian cancer patients don’t always have the ability or opportunity to … Continued

Discovery of New Gene Mutation That Increases Ovarian Cance...

Discovery of New Gene Mutation That Increases Ovarian Cancer Risk, Passed Down Through Paternal Lineage

(February 22, 2018) Researchers at Roswell Park Comprehensive Cancer Center, including Kunle Odunsi, MD, PhD, senior author of the study and current OCRFA Scientific Advisory Committee member, have discovered a mutation of an unidentified gene that increases both the risk of early onset ovarian cancer and prostate cancer. Using the Familial Ovarian Cancer Registry at … Continued

US Preventive Services Task Force: Ovarian Cancer Screening...

US Preventive Services Task Force: Ovarian Cancer Screening Not Effective for Low-Risk Women

(February 14, 2018) Today the US Preventive Task Force updated their recommendation on ovarian cancer screening, reaffirming their 2012 position that screening average risk women for ovarian cancer is not effective in reducing mortality from the disease. Furthermore, they stated that screening for ovarian cancer carries certain risk and harms that may be substantial, and … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.